Effects of virtual reality-based rehabilitation on cognitive function and mood in multiple sclerosis: A systematic review and meta-analysis of randomized controlled trials
Jiongliang Zhang,Minmin Wu,Jinting Li,Wenjing Song,Xiaoguang Lin,Luwen Zhu
DOI: https://doi.org/10.1016/j.msard.2024.105643
IF: 4.808
2024-05-13
Multiple Sclerosis and Related Disorders
Abstract:Background Multiple sclerosis (MS) is a disabling neurological disease that causes cognitive impairment and mental problems that occur in all MS phenotypes but are most common in patients with secondary progressive MS. Various degrees of cognitive impairment and mental health concerns are common among patients with MS (PwMS). Virtual reality (VR)-based rehabilitation is an innovative approach aimed at enhancing cognitive function and mood in PwMS. This study aims to perform a meta-analysis to assess the effects of VR-based rehabilitation on cognitive function and mood in PwMS. Methods Using PubMed, Embase, the Cochrane Library, Web of Science, and the Physiotherapy Evidence Database (PEDro), a thorough database search was performed to identify randomized controlled trials (RCTs) examining the effects of VR on PwMS. Trials published until October 31, 2023, that satisfied our predetermined inclusion and exclusion criteria were included. Data were extracted, literature was examined, and the methodological quality of the included trials was assessed. StataSE version 16 was used for the meta-analysis. Results Our meta-analysis included 461 patients from 10 RCTs. Primary outcomes: The Montreal Cognitive Assessment (MoCA) (weighted mean difference [WMD]=1.93, 95 % confidence interval [CI]=0.51–3.36, P = 0.008, I2 = 75.4 %) the Spatial Recall Test (SPART) (WMD=3.57, 95 % CI=1.65–5.50, P < 0.001, I2 = 0 %), immediate recall (standard mean difference [SMD]=0.37, 95 % CI=0.10–0.64, P = 0.007, I2 = 0 %) and delayed recall ([SMD]=0.30, 95 % CI=0.06–0.54, P = 0.013, I2 = 35.4 %) showed improvements in comparison to the control group in terms of global cognitive function immediate recall, delayed recall, and visuospatial abilities. Secondary outcomes: Compared to the control group, anxiety improved (standard mean difference [SMD]=0.36, 95 % CI=0.10–0.62, P = 0.007, I2 = 43.1 %). However, there were no significant differences in processing speed, attention, working memory or depression. Conclusions This systematic review provides valuable evidence for improving cognitive function and mood in PwMS through VR-based rehabilitation. In the future, VR-based rehabilitation may be a potential method to treat cognitive function and emotional symptoms of MS. Systematic review registration PROSPERO; identifier: CRD42023474467.
clinical neurology